Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow AVENUE THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for AVENUE THERAPEUTICS, INC.

ATXI

AVENUE THERAPEUTICS, INC.

About AVENUE THERAPEUTICS, INC.

Avenue Therapeutics, Inc. is a specialty pharmaceutical company developing therapies for neurologic diseases. Its pipeline includes AJ201 for spinal and bulbar muscular atrophy, IV tramadol for postoperative acute pain, and BAER-101 for epilepsy and panic disorders. Avenue focuses on advancing clinical-stage drug candidates with novel mechanisms, targeting unmet medical needs in neurology and pain management, leveraging licensing agreements and clinical development to bring innovative treatments to market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from AVENUE THERAPEUTICS, INC.

1
1
AVENUE THERAPEUTICS, INC. Avenue Therapeutics Reports $695,000 Net Loss in Q1 2026, Improves from $1.9 Million Loss in Q1 2025

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
AVENUE THERAPEUTICS, INC. Avenue Therapeutics Reports Reduced Net Loss and Strategic Changes in Product Pipeline

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
AVENUE THERAPEUTICS, INC. Avenue Therapeutics Reports Reduced Net Losses and Revenue Growth in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
AVENUE THERAPEUTICS, INC. Avenue Therapeutics Reports Net Income of $329,000 in Q2 2025, Significant Financial Improvement

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
AVENUE THERAPEUTICS, INC. Avenue Therapeutics Reports $1.9 Million Net Loss in Q1 2025, Sees Improvement Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
AVENUE THERAPEUTICS, INC. Avenue Therapeutics Reports $11.7 Million Net Loss for 2024, Cash Reserves Increase

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
AVENUE THERAPEUTICS, INC. Avenue Therapeutics Reports Net Loss and Increased Research Expenses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments